12 Month Price Forecast For ELV
Distance to ELV Price Forecasts
ELV Price Momentum
🤔 Considering Elevance (ELV)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 10, 2025 4:15 PM UTC
ELV Analyst Ratings & Price Targets
Based on our analysis of 24 Wall Street analysts, ELV has a consensus that is bullish. The median price target is $480.00, with forecasts ranging from $405.00 to $625.00. Currently, there are 17 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
With ELV currently trading at $391.42, the median price forecast suggests a 22.6% upside. The most optimistic forecast comes from at , projecting a 59.7% upside, while at provides the most conservative target, suggesting a 3.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELV Analyst Consensus
ELV Price Target Range
Latest ELV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 29, 2025 | Argus Research | David Toung | Hold | Reiterates | $405.40 |
| Jan 28, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $478.00 |
| Jan 24, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $512.00 |
| Jan 24, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $485.00 |
| Jan 6, 2025 | Truist Securities | Buy | Maintains | $0.00 | |
| Nov 5, 2024 | Mizuho | Ann Hynes | Outperform | Maintains | $505.00 |
| Nov 4, 2024 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $495.00 |
| Oct 23, 2024 | Morgan Stanley | Erin Wright | Overweight | Maintains | $551.00 |
| Oct 22, 2024 | Barclays | Andrew Mok | Overweight | Maintains | $501.00 |
| Oct 21, 2024 | TD Cowen | Ryan Langston | Buy | Maintains | $484.00 |
| Oct 18, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $478.00 |
| Oct 18, 2024 | UBS | A.J. Rice | Buy | Maintains | $555.00 |
| Oct 18, 2024 | Argus Research | Hold | Downgrade | $0.00 | |
| Oct 18, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $485.00 |
| Oct 18, 2024 | Truist Securities | David Macdonald | Buy | Reiterates | $520.00 |
| Oct 10, 2024 | Barclays | Andrew Mok | Overweight | Maintains | $622.00 |
| Oct 1, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $600.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $600.00 |
| Sep 10, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $600.00 |
| Sep 5, 2024 | Stephens & Co. | Scott Fidel | Overweight | Reiterates | $615.00 |
Stocks Similar to Elevance Health, Inc.
The following stocks are similar to Elevance based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Elevance Health, Inc. (ELV) Financial Data
Elevance Health, Inc. has a market capitalization of $90.78B with a P/E ratio of 15.2x. The company generates $174.02B in trailing twelve-month revenue with a 3.7% profit margin.
Revenue growth is +5.4% quarter-over-quarter, while maintaining an operating margin of +4.4% and return on equity of +15.5%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Elevance Health, Inc. (ELV) Company Overview
About Elevance Health, Inc.
Health benefits and services provider in the U.S.
The company operates a diversified health benefits model through segments including Health Benefits, CarelonRx, and Carelon Services. It generates revenue by offering a variety of health plans, specialty insurance products, and pharmacy services, including pharmacy benefit management and claims adjudication.
Elevance Health, Inc. operates under well-known brands like Anthem Blue Cross and Blue Shield and has a strong presence in the healthcare market since its incorporation in 2001. The company focuses on comprehensive healthcare-related services, including behavioral health and integrated care delivery, positioning itself as a key player in the evolving health benefits landscape.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
104,900
CEO
Ms. Gail Koziara Boudreaux
Country
United States
IPO Year
2022
Website
www.elevancehealth.comElevance Health, Inc. (ELV) Latest News & Analysis
Elevance Health Foundation has launched a five-year, $150 million initiative to improve health in under-resourced communities, focusing on physical, behavioral, and social needs through various strategies.
Elevance Health's $150 million commitment signals a strong focus on community health initiatives, potentially enhancing its brand reputation and driving long-term growth in underserved markets.
Alphabet's Verily is selling its subsidiary, Granular Insurance Company, to Elevance Health. Granular was launched in 2020 with support from Swiss Re's insurance unit.
Verily's sale of Granular Insurance to Elevance Health signals a strategic shift, potentially impacting its focus and financial health, influencing investor sentiment and stock performance.
The SPDR S&P 500 ETF gained 2.67% in January 2025. The top 15 dividend growth stocks for February yield 1.64% and are 25% undervalued, with an 11.03% CAGR since September 2020.
The SPDR S&P 500 ETF's January gain signals market strength. The undervaluation of dividend stocks suggests potential for price appreciation and income generation, appealing to yield-focused investors.
Trump has pledged to protect Social Security, Medicare, and now Medicaid during his campaign, which may affect healthcare sector investments.
Trump's inclusion of Medicaid in his campaign promises may signal increased government spending and potential changes in healthcare policy, impacting related sectors and overall market sentiment.
LCH Investments reports that over 200 hedge funds, known as Tiger Cubs, have been established by former employees of the iconic Tiger Management founded by Julian Robertson.
The presence of over 200 Tiger Cubs indicates a significant influence on market strategies, potentially impacting investment trends and performance in various sectors.
In the first earnings season of 2025, companies are announcing share buyback programs and dividend increases, which may impact investor sentiment and stock performance.
Earnings season can impact stock prices and investor sentiment. Share buybacks and dividend increases signal company confidence and can enhance shareholder value, potentially driving stock performance higher.
Frequently Asked Questions About ELV Stock
What is Elevance Health, Inc.'s (ELV) stock forecast for 2025?
Based on our analysis of 24 Wall Street analysts, Elevance Health, Inc. (ELV) has a median price target of $480.00. The highest price target is $625.00 and the lowest is $405.00.
Is ELV stock a good investment in 2025?
According to current analyst ratings, ELV has 17 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $391.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ELV stock?
Wall Street analysts predict ELV stock could reach $480.00 in the next 12 months. This represents a 22.6% increase from the current price of $391.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elevance Health, Inc.'s business model?
The company operates a diversified health benefits model through segments including Health Benefits, CarelonRx, and Carelon Services. It generates revenue by offering a variety of health plans, specialty insurance products, and pharmacy services, including pharmacy benefit management and claims adjudication.
What is the highest forecasted price for ELV Elevance Health, Inc.?
The highest price target for ELV is $625.00 from at , which represents a 59.7% increase from the current price of $391.42.
What is the lowest forecasted price for ELV Elevance Health, Inc.?
The lowest price target for ELV is $405.00 from at , which represents a 3.5% increase from the current price of $391.42.
What is the overall ELV consensus from analysts for Elevance Health, Inc.?
The overall analyst consensus for ELV is bullish. Out of 24 Wall Street analysts, 17 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $480.00.
How accurate are ELV stock price projections?
Stock price projections, including those for Elevance Health, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
